Surgical resection is the most common and effective option for the clinical treatment of
lung cancer.
Postoperative pain may activate surgically induced stress response, leading to a decrease in human immune function. However, conventional
analgesics such as
morphine and its derivatives have been reported to have immunosuppressive side effects. In the critical period after surgery, the immunosuppressive effect of
analgesics on patients with
lung cancer could promote postoperative
cancer recurrence and
metastasis. Therefore, it will be an ideal scenario for
postoperative pain management to maximize
pain relief while minimizing immunosuppression side effects. In this study, we found that a novel mixed agonist-
antagonist opioid analgesic,
dezocine, significantly promoted the morphological maturation of dendritic cells (DCs), and increase the expression of DCs-related surface markers in postoperative peripheral blood of patients with
lung cancer. Furthermore,
dezocine-matured DCs increased the general immune response by promoting the secretion of
IL-12 and
IL-6 cytokines and enhancing the proliferation and cytotoxicity of CD8+ T cells. Then genome-wide transcriptomic profiling analyses were performed to identify the specific gene expression of
dezocine-matured DCs. The results of transcriptomic analysis as well as in vitro validation showed that the upregulation of CXCL10, CD3G, and GRB2 were significantly associated with
dezocine-induced DCs maturation. Overall, our data showed that
dezocine might exhibit unique properties by acting as an
immunostimulant, which provides new evidence for its application in
postoperative pain management of patients with
lung cancer.